RxDoctor Payments Data

Binghua Zhu, MD

Internal Medicine · Springfield, NJNPI 1851547889

Payments from drug & device makers

$606in general payments, 2019–2025

Across 40 payments — averaging $15.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$329
  • Exact Sciences$163
  • Lilly USA, LLC$39
  • Amgen$32
  • Merck$27
  • AstraZeneca$16

What the payments were for

  • Food & beverage$59598%
  • Education$122%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie25$329
Exact Sciences7$163
Lilly USA, LLC3$39
Amgen2$32
Merck2$27
AstraZeneca1$16

How this compares

$606 in reported general payments places this provider in the 55th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$134,184
Medicare patients
222
Services billed
1,361

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin74$89,144
FarxigaDapagliflozin Propanediol53$56,629
LinzessLinaclotide62$54,740
EliquisApixaban30$35,870
RybelsusSemaglutide15$27,950
ProliaDenosumab17$26,658
TrulicityDulaglutide13$23,993
CreonLipase/Protease/Amylase12$22,445
JanuviaSitagliptin Phosphate18$21,532
MounjaroTirzepatide17$20,881
XareltoRivaroxaban18$17,070
Combivent RespimatIpratropium/Albuterol Sulfate28$13,380
OzempicSemaglutide12$13,099
TradjentaLinagliptin20$12,638
Breo ElliptaFluticasone/Vilanterol28$10,338

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$329$77,18574 claims
AstraZenecaFarxiga$16$56,62953 claims
Lilly USA, LLCTrulicity, Mounjaro$39$44,87430 claims
AmgenProlia$32$26,65817 claims
MerckJanuvia$27$21,53218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Springfield

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →